A lab-made cousin of coenzyme Q10 that supports cell energy and acts as an antioxidant, reaching the brain even when normal cell-energy machinery is faulty. Its standout, well-supported benefit is preserving vision in a rare inherited eye disease. Beyond that the evidence thins; the general healthy-aging case rests on mechanism, not human outcomes. (Full Review)
| Marker | Target | Why |
|---|---|---|
| ALT (alanine aminotransferase) | ~10–26 U/L (functional); conventional up to ~40–55 U/L | Detects hepatic stress from heavy first-pass metabolism |
| AST (aspartate aminotransferase) | ~10–26 U/L (functional); conventional up to ~40 U/L | Complements ALT for liver-cell injury |
| GGT (gamma-glutamyl transferase) | <20 U/L (functional); conventional up to ~40–60 U/L | Sensitive marker of hepatic and oxidative-stress burden |
| Bilirubin (total) | 0.3–1.0 mg/dL | Screens overall hepatic clearance and processing |
| Visual acuity (LogMAR), if used for optic indication | Improvement or stabilization vs. baseline | Tracks the one outcome with high-quality idebenone evidence |
Cadence: Liver enzymes at baseline, again at ~4–8 weeks after initiation, then every 3–6 months during continued use; more frequent with hepatic concerns.